VinaR - Repository of the Vinča Nuclear Institute
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   Vinar
  • Vinča
  • Radovi istraživača
  • View Item
  •   Vinar
  • Vinča
  • Radovi istraživača
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI

No Thumbnail
Authors
Životić, Ivan
Đurić, Tamara
Stanković, Aleksandra
Milašinović, Dejan
Stanković, Goran
Dekleva, Milica
Marković-Nikolić, Nataša
Alavantić, Dragan
Živković, Maja
Article (Published version)
,
© 2019 The Canadian Society of Clinical Chemists
Metadata
Show full item record
Abstract
Background: Chromosomal region 9p21.3 is most robustly associated with coronary artery disease (CAD) in western European populations. However, heterogeneity in CAD phenotypes leads to uncertainty whether 9p21.3 is associated with stable and/or acute clinical presentations of CAD. 9p21.3 is rich in regulatory elements, but the underlying mechanisms of its actions in CAD remain unclear. We investigate the association of 9p21.3 two haplotype blocks lead variants (rs10757278 and rs518394) with first-ever non-fatal myocardial infarction (MI) in CAD patients and their association with CDKN2B mRNA expression in peripheral blood mononuclear cells 6 months after the event. Methods: We included CAD patients with sustained first MI (n = 523) and controls (n = 583). Gene expression was assessed in 72 patients 6 months after MI and 43 healthy controls. TaqMan® technology was used for the gene expression and genotyping analysis. Results: CDKN2B mRNA was significantly lower in MI patients compared wi...th the controls (p = 0.002) and in patients carrying the rs10757278 G risk allele versus AA homozygotes (p = 0.012) 6 months after the event. While we confirmed the association of rs10757278 with CDKN2B expression in MI patients, we failed to find an association between the investigated variants and MI or disease burden. Conclusions: We suggest a dysregulation of gene expression in the 9p21.3 region six months after acute MI, which is affected by a genetic variant in patients. The rs10757278 rare allele is one factor that might lead to prolonged risk for proatherogenic complications. © 2019 The Canadian Society of Clinical Chemists

Keywords:
Myocardial infarction / 9p21 / CDKN2B / rs10757278 / rs518394 / Atherosclerosis
Source:
Clinical Biochemistry, 2019, 73, 70-76
Funding / projects:
  • An integral study to identify the regional genetic and environmental risk factors for the common noncommunicable diseases in the human population of Serbia - INGEMA_S (RS-41028)
  • Genetic basis of human vascular and inflammatory diseases (RS-175085)

DOI: 10.1016/j.clinbiochem.2019.08.003

ISSN: 0009-9120

PubMed: 31386834

WoS: 000492745500010

Scopus: 2-s2.0-85070518697
[ Google Scholar ]
3
3
URI
https://vinar.vin.bg.ac.rs/handle/123456789/8432
Collections
  • Radovi istraživača
Institution/Community
Vinča
TY  - JOUR
AU  - Životić, Ivan
AU  - Đurić, Tamara
AU  - Stanković, Aleksandra
AU  - Milašinović, Dejan
AU  - Stanković, Goran
AU  - Dekleva, Milica
AU  - Marković-Nikolić, Nataša
AU  - Alavantić, Dragan
AU  - Živković, Maja
PY  - 2019
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8432
AB  - Background: Chromosomal region 9p21.3 is most robustly associated with coronary artery disease (CAD) in western European populations. However, heterogeneity in CAD phenotypes leads to uncertainty whether 9p21.3 is associated with stable and/or acute clinical presentations of CAD. 9p21.3 is rich in regulatory elements, but the underlying mechanisms of its actions in CAD remain unclear. We investigate the association of 9p21.3 two haplotype blocks lead variants (rs10757278 and rs518394) with first-ever non-fatal myocardial infarction (MI) in CAD patients and their association with CDKN2B mRNA expression in peripheral blood mononuclear cells 6 months after the event. Methods: We included CAD patients with sustained first MI (n = 523) and controls (n = 583). Gene expression was assessed in 72 patients 6 months after MI and 43 healthy controls. TaqMan® technology was used for the gene expression and genotyping analysis. Results: CDKN2B mRNA was significantly lower in MI patients compared with the controls (p = 0.002) and in patients carrying the rs10757278 G risk allele versus AA homozygotes (p = 0.012) 6 months after the event. While we confirmed the association of rs10757278 with CDKN2B expression in MI patients, we failed to find an association between the investigated variants and MI or disease burden. Conclusions: We suggest a dysregulation of gene expression in the 9p21.3 region six months after acute MI, which is affected by a genetic variant in patients. The rs10757278 rare allele is one factor that might lead to prolonged risk for proatherogenic complications. © 2019 The Canadian Society of Clinical Chemists
T2  - Clinical Biochemistry
T1  - CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI
VL  - 73
SP  - 70
EP  - 76
DO  - 10.1016/j.clinbiochem.2019.08.003
ER  - 
@article{
author = "Životić, Ivan and Đurić, Tamara and Stanković, Aleksandra and Milašinović, Dejan and Stanković, Goran and Dekleva, Milica and Marković-Nikolić, Nataša and Alavantić, Dragan and Živković, Maja",
year = "2019",
abstract = "Background: Chromosomal region 9p21.3 is most robustly associated with coronary artery disease (CAD) in western European populations. However, heterogeneity in CAD phenotypes leads to uncertainty whether 9p21.3 is associated with stable and/or acute clinical presentations of CAD. 9p21.3 is rich in regulatory elements, but the underlying mechanisms of its actions in CAD remain unclear. We investigate the association of 9p21.3 two haplotype blocks lead variants (rs10757278 and rs518394) with first-ever non-fatal myocardial infarction (MI) in CAD patients and their association with CDKN2B mRNA expression in peripheral blood mononuclear cells 6 months after the event. Methods: We included CAD patients with sustained first MI (n = 523) and controls (n = 583). Gene expression was assessed in 72 patients 6 months after MI and 43 healthy controls. TaqMan® technology was used for the gene expression and genotyping analysis. Results: CDKN2B mRNA was significantly lower in MI patients compared with the controls (p = 0.002) and in patients carrying the rs10757278 G risk allele versus AA homozygotes (p = 0.012) 6 months after the event. While we confirmed the association of rs10757278 with CDKN2B expression in MI patients, we failed to find an association between the investigated variants and MI or disease burden. Conclusions: We suggest a dysregulation of gene expression in the 9p21.3 region six months after acute MI, which is affected by a genetic variant in patients. The rs10757278 rare allele is one factor that might lead to prolonged risk for proatherogenic complications. © 2019 The Canadian Society of Clinical Chemists",
journal = "Clinical Biochemistry",
title = "CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI",
volume = "73",
pages = "70-76",
doi = "10.1016/j.clinbiochem.2019.08.003"
}
Životić, I., Đurić, T., Stanković, A., Milašinović, D., Stanković, G., Dekleva, M., Marković-Nikolić, N., Alavantić, D.,& Živković, M.. (2019). CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI. in Clinical Biochemistry, 73, 70-76.
https://doi.org/10.1016/j.clinbiochem.2019.08.003
Životić I, Đurić T, Stanković A, Milašinović D, Stanković G, Dekleva M, Marković-Nikolić N, Alavantić D, Živković M. CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI. in Clinical Biochemistry. 2019;73:70-76.
doi:10.1016/j.clinbiochem.2019.08.003 .
Životić, Ivan, Đurić, Tamara, Stanković, Aleksandra, Milašinović, Dejan, Stanković, Goran, Dekleva, Milica, Marković-Nikolić, Nataša, Alavantić, Dragan, Živković, Maja, "CDKN2B gene expression is affected by 9p21.3 rs10757278 in CAD patients, six months after the MI" in Clinical Biochemistry, 73 (2019):70-76,
https://doi.org/10.1016/j.clinbiochem.2019.08.003 . .

DSpace software copyright © 2002-2015  DuraSpace
About the VinaR Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceInstitutions/communitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About the VinaR Repository | Send Feedback

OpenAIRERCUB